Novavax mentioned its NVX-CoV2373 demonstrated a 90% efficacy in section 3 trials within the UK, taking it nearer to approval by the UK well being authorities. J&J’s single-dose vaccine confirmed an total efficacy of 66% and 85% efficacy in stopping dying (extreme illness) throughout all age and ethnic teams.
“The potential to significantly reduce the burden of severe disease, by providing an effective and well-tolerated vaccine with just one immunisation, is a critical component of the global public health response,” mentioned Paul Stoffels, vice chairman of the manager committee and chief scientific officer at J&J.
Separate Trial in US
Novavax enrolled greater than 15,000 individuals aged 18-84 years, of whom 27% had been over 65. The vaccine was proven to work towards the extra infectious UK pressure. However, its efficacy towards the group detected with the South Africa pressure was 60%. Novavax is working a separate trial within the US, the place it has recruited 16,000 individuals and is predicted to enrol one other 14,000 by February. The firm has already submitted knowledge for approval to the UK authorities.
“The efficacy shown against the emerging variants is also extremely encouraging,” mentioned Clive Dix, chair of the UK Vaccine Taskforce, in a press release concerning the Novavax candidate. “This is an incredible achievement that will ensure we can protect individuals in the UK and the rest of the world from this virus.”
J&J is predicted to submit its vaccine for approval to the US authorities subsequent week. It mentioned its vaccine had the next efficacy amongst US individuals. Against the South Africa variant, its efficacy was 57%.
Novavax has obtained $15 million from the Coalition of Epidemic Preparedness and Innovations and the Bill and Melinda Gates Foundation for growing the vaccine for the WHO’s COVAX facility.